AIM ImmunoTech (NYSE:AIM – Get Free Report) had its price target reduced by stock analysts at Maxim Group from $2.00 to $1.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Maxim Group’s price target would suggest a potential upside of 284.76% from the stock’s current price.
Separately, Ascendiant Capital Markets reduced their target price on shares of AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd.
Get Our Latest Analysis on AIM ImmunoTech
AIM ImmunoTech Stock Down 3.4 %
AIM ImmunoTech (NYSE:AIM – Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.03) EPS for the quarter. AIM ImmunoTech had a negative net margin of 13,952.74% and a negative return on equity of 269.04%. The firm had revenue of $0.05 million during the quarter. As a group, sell-side analysts anticipate that AIM ImmunoTech will post -0.35 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in AIM ImmunoTech stock. Armistice Capital LLC purchased a new position in shares of AIM ImmunoTech Inc. (NYSE:AIM – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned about 7.92% of AIM ImmunoTech as of its most recent filing with the SEC. Institutional investors and hedge funds own 12.02% of the company’s stock.
About AIM ImmunoTech
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
Read More
- Five stocks we like better than AIM ImmunoTech
- How to Calculate Stock Profit
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What is the FTSE 100 index?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.